Skinny Stent Comes Up Short, Troponin ‘Noise’ Blamed
The Slender IDS trial was left underpowered for noninferiority, observers said. ‘In study after study,’ said one, ‘we are now overreacting’ to biomarker elevations ‘that have zero clinical relevance.’